BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients
with NSCLC who have received previous treatment with at least one but not more than two lines
of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either
gefitinib or erlotinib for a period of at least 12 weeks and then progressed.
The primary objective of this randomized trial is to determine the efficacy of BIBW 2992 as a
single agent (Arm A) as compared to a matching placebo (Arm B) in this patient population.
Patients on both treatment arms will receive best supportive care in addition to study
treatment.
Patients enrolled into the trial will be treated and followed until death or lost to
follow-up.